ORIC Pharmaceuticals to Host Conference Call with KOL to Review Initial Data Being Presented at ASCO from Phase 1b Study of ORIC-101 in Combination with Nab-paclitaxel

Rhea-AI Summary

ORIC Pharmaceuticals has announced a conference call and webcast on June 2, 2021, at 5:00 p.m. ET to review initial data from the ongoing Phase 1b study of ORIC-101, a glucocorticoid receptor antagonist combined with nab-paclitaxel for advanced solid tumors. The data will also be presented at the ASCO Annual Meeting from June 4-8, 2021. ORIC-101 is part of two Phase 1b trials addressing therapeutic resistance in cancer. The call will feature insights from Professor Pamela Munster, a key investigator.

Positive

• Scheduled presentation of initial data from Phase 1b study of ORIC-101, indicating potential progress in cancer treatment.
• Participation of a prominent investigator, Professor Pamela Munster, enhances credibility of study findings.

Negative

• None.

Webcast event scheduled for Wednesday, June 2, 2021, at 5:00 p.m. ET

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that the company will host a conference call and webcast to review initial data from the ongoing Phase 1b study of ORIC-101, a glucocorticoid receptor antagonist, in combination with nab-paclitaxel in advanced solid tumors. On the conference call, management will be joined by trial investigator and senior author, Professor Pamela Munster, M.D., Director of the Early Phase Clinical Trials Unit and Co-Leader of the Center for BRCA Research at the University of California San Francisco. The data will also be presented in two posters at the American Society of Clinical Oncology (ASCO) Annual Meeting to be held June 4 – 8, 2021.

Webcast and Conference Call

ORIC will host a conference call and webcast, Wednesday, June 2, 2021, at 5:00 p.m. ET. To participate in the conference call, please dial (833) 651-0991 (domestic) or (918) 922-6080 (international) and refer to conference ID 4783288. A live webcast and audio archive of the conference call will be available through the investor section of the company’s website at www.oricpharma.com. The webcast will be available for replay for 90 days following the presentation.

About ORIC Pharmaceuticals, Inc.

ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s lead product candidate, ORIC-101, is a potent and selective small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across a variety of solid tumors. ORIC-101 is currently in two separate Phase 1b trials in combination with (1) Abraxane (nab-paclitaxel) in advanced or metastatic solid tumors and (2) Xtandi (enzalutamide) in metastatic prostate cancer. ORIC’s other product candidates include (1) ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens, (2) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (3) ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers. Beyond these four product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on Twitter or LinkedIn.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, statements regarding the expected timing of reporting initial data from the Phase 1b study of ORIC-101 in combination with nab-paclitaxel and plans underlying any of ORIC’s other programs. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. The forward-looking statements contained herein are based upon ORIC’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those projected in any forward-looking statements due to numerous risks and uncertainties, including but not limited to: risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics and operating as an early clinical stage company; ORIC’s ability to develop, initiate or complete preclinical studies and clinical trials for, obtain approvals for and commercialize any of its product candidates; changes in ORIC’s plans to develop and commercialize its product candidates; the potential for clinical trials of ORIC-101, ORIC-533, ORIC-944, ORIC-114 or any other product candidates to differ from preclinical, interim, preliminary or expected results; negative impacts of the COVID-19 pandemic on ORIC’s operations, including clinical trials; the risk of the occurrence of any event, change or other circumstance that could give rise to the termination of ORIC’s license agreements; ORIC’s ability to raise any additional funding it will need to continue to pursue its business and product development plans; regulatory developments in the United States and foreign countries; ORIC’s reliance on third parties, including contract manufacturers and contract research organizations; ORIC’s ability to obtain and maintain intellectual property protection for its product candidates; the loss of key scientific or management personnel; competition in the industry in which ORIC operates; general economic and market conditions; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in ORIC’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on May 6, 2021, and ORIC’s future reports to be filed with the SEC. These forward-looking statements are made as of the date of this press release, and ORIC assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.

Investor Contact:
Dominic Piscitelli, Chief Financial Officer
dominic.piscitelli@oricpharma.com
info@oricpharma.com

FAQ

What is the purpose of the Phase 1b study of ORIC-101?

The Phase 1b study aims to evaluate the efficacy of ORIC-101 in combination with nab-paclitaxel for treating advanced solid tumors, addressing therapeutic resistance.

When will the initial data from the ORIC-101 trial be released?

Initial data from the ORIC-101 trial will be discussed during the conference call on June 2, 2021.

Where can I find the presentation of ORIC-101 data?

The data will be presented during a conference call and webcast on June 2, and also at the ASCO Annual Meeting from June 4-8, 2021.

Who will be presenting data on ORIC-101?

Professor Pamela Munster, a trial investigator and senior author, will present the data during the conference call.

What is ORIC Pharmaceuticals focusing on?

ORIC Pharmaceuticals focuses on developing treatments that address mechanisms of therapeutic resistance in cancer.